OverviewSuggest Edit

Progenity is a company providing molecular and specialized diagnostic tests. It offers the Preparent Carrier Test for genetic diseases, the Innatal Prenatal Screen for chromosomal disorders, and the Riscover Hereditary Cancer Test for hereditary cancer risk. In addition, the company develops the Resura Prenatal Test for monogenic diseases.

TypePublic
Founded2010
HQSan Diego, CA, US
Websiteprogenity.com
Employee Ratings3

Latest Updates

Employees (est.) (Jun 2020)674
Job Openings7
Revenue (FY, 2020)$74.3 M
Share Price (Jul 2021)$2.5(-3%)

Key People/Management at Progenity

Harry Stylli

Harry Stylli

CEO and Chairman of the Board, Founder
Kevin Howe

Kevin Howe

Senior Vice President, Strategic Operations
Matthew Cooper

Matthew Cooper

Chief Scientific Officer
Clarke Neumann

Clarke Neumann

Senior Vice President, General Counsel and Secretary
Sami Shihabi

Sami Shihabi

Chief Commercial Officer
Troy Seelye

Troy Seelye

Chief Information Officer
Show more

Progenity Office Locations

Progenity has offices in San Diego, Ann Arbor and Detroit
San Diego, CA, US (HQ)
4330 La Jolla Village Dr #200
Ann Arbor, MI, US
5230 S State Rd
Detroit, MI, US
PO Box 674425
Show all (3)

Progenity Financials and Metrics

Progenity Revenue

Progenity's revenue was reported to be $74.31 m in FY, 2020
USD

Revenue (Q1, 2021)

24.5m

Gross profit (Q1, 2021)

2.3m

Gross profit margin (Q1, 2021), %

9.3%

Net income (Q1, 2021)

(32.3m)

EBIT (Q1, 2021)

(46.2m)

Market capitalization (23-Jul-2021)

151.2m

Closing stock price (23-Jul-2021)

2.5

Cash (31-Mar-2021)

65.3m

EV

86.1m
Progenity's current market capitalization is $151.2 m.
Annual
USDFY, 2020

Revenue

74.3m

Cost of goods sold

93.4m

Gross profit

(19.1m)

Gross profit Margin, %

(26%)
Quarterly
USDQ2, 2020Q1, 2021

Revenue

17.3m24.5m

Cost of goods sold

21.8m22.2m

Gross profit

(4.6m)2.3m

Gross profit Margin, %

(26%)9%
Annual
USDFY, 2020

Cash

92.1m

Accounts Receivable

12.7m

Prepaid Expenses

9.4m

Inventories

12.2m
Quarterly
USDQ2, 2020Q1, 2021

Cash

113.6m65.3m

Accounts Receivable

14.4m13.2m

Prepaid Expenses

6.1m10.3m

Inventories

10.2m12.4m
Annual
USDFY, 2020

Net Income

(192.5m)

Depreciation and Amortization

5.1m

Inventories

(1.4m)

Accounts Payable

2.9m
Quarterly
USDQ2, 2020Q1, 2021

Net Income

(69.9m)(32.3m)

Depreciation and Amortization

2.5m1.2m

Inventories

685.0k(336.0k)

Accounts Payable

380.0k(2.2m)
USDQ2, 2020

EV/EBIT

-6.3 x

EV/CFO

-6.6 x

Revenue/Employee

32.9k

Financial Leverage

-10.9 x
Show all financial metrics

Progenity Online and Social Media Presence

Embed Graph

Progenity News and Updates

Progenity Announces Appointment of Surbhi Sarna to its Board of Directors

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi’s medical device experience and her focus on development of strategic partnership…

PROGENITY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Progenity, Inc. - PROG

NEW ORLEANS, June 25, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Progenity, Inc. (NasdaqGM: PROG). In August 2020, the Company...

Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board. The advisory board includes respected researchers and clinicians who are thought leaders in the…

Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Raymond James 2021 Human Health Inno…

NASDAQ: PROG Investor Notice: Update in Lawsuit against Progenity, Inc. announced by Shareholders Foundation

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that an update in the lawsuit that is pending for certain investors in NASDAQ: PROG shares.

Progenity Announces $40 Million Private Placement

SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting …
Show more

Progenity Frequently Asked Questions

  • When was Progenity founded?

    Progenity was founded in 2010.

  • Who are Progenity key executives?

    Progenity's key executives are Harry Stylli, Kevin Howe and Matthew Cooper.

  • How many employees does Progenity have?

    Progenity has 674 employees.

  • What is Progenity revenue?

    Latest Progenity annual revenue is $74.3 m.

  • What is Progenity revenue per employee?

    Latest Progenity revenue per employee is $110.3 k.

  • Who are Progenity competitors?

    Competitors of Progenity include GeneDx, Ambry Genetics and Natera.

  • Where is Progenity headquarters?

    Progenity headquarters is located at 4330 La Jolla Village Dr #200, San Diego.

  • Where are Progenity offices?

    Progenity has offices in San Diego, Ann Arbor and Detroit.

  • How many offices does Progenity have?

    Progenity has 3 offices.